Repligen Corporation with ticker code (RGEN) now have 10 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $225.00 and $165.00 with the average share target price sitting at $204.08. (at the time of writing). Given that the stocks previous close was at $125.94 and the analysts are correct then there would likely be a percentage uptick in value of 62.0%. The 50 day MA is $161.83 and the 200 moving average now moves to $169.21. The company has a market cap of 7.00B. The stock price is currently at: $125.27 USD
The potential market cap would be $11,342,489,004 based on the market consensus.
The company has a dividend yield of 5.38%. Other points of data to note are a P/E ratio of 481.81, revenue per share of $10.89 and a 0.6% return on assets.
Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company’s bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.
